Novem Group Acquires New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

Novem Group bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,646 shares of the biopharmaceutical company's stock, valued at approximately $409,000.

Several other institutional investors have also recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the 1st quarter worth approximately $25,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the 1st quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC increased its holdings in Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 216 shares in the last quarter. Investment Research & Advisory Group Inc. raised its position in Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. Finally, Synergy Investment Management LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $40,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer owned 620,268 shares in the company, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 0.2%

NASDAQ GILD opened at $111.28 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96. The business has a 50 day moving average price of $106.85 and a 200-day moving average price of $103.80. The company has a market cap of $138.42 billion, a price-to-earnings ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the firm posted ($1.32) EPS. Gilead Sciences's revenue was down .3% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.84%. Gilead Sciences's payout ratio is 66.53%.

Analyst Ratings Changes

A number of equities analysts have recently commented on GILD shares. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Morgan Stanley boosted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.